AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer
BackgroundAlthough immunotherapy has been used in the treatment of metastatic triple negative breast cancer (TNBC), its therapeutic influence on human epidermal growth factor receptor 2 (HER2)-positive subtype remains controversial. It is therefore imperative to find biomarkers that can predict the...
Enregistré dans:
Auteurs principaux: | Long Wang, Xue Zhang, Mengxue Wang, Yunhai Li, Jiali Xu, Jiaying Wei, Hongzhong Li, Guosheng Ren, Xuedong Yin |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b1b49b8e9b304d6ebdae4cb24b502b3a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
par: Cor J. Ravensbergen, et autres
Publié: (2021) -
A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy
par: Chenyu Mao, et autres
Publié: (2021) -
Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients
par: Gedmante Radziuviene, et autres
Publié: (2021) -
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
par: Ayoub NM, et autres
Publié: (2019) -
The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
par: Ilana Schlam, et autres
Publié: (2021)